REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
Sitemap
Information about DRd does not appear in the REVLIMID full Prescribing Information. Please see the daratumumab full Prescribing Information for a complete discussion of Important Safety Information at www.darzalexhcp.com/iv.